The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InHeartFlow has announced robust financial results for 2025, recording a 40% surge in sales with total revenue exceeding $176 million. The company's growth is primarily driven by the increasing adoption of its AI-powered cardiac diagnostic platform and FDA-cleared next-generation algorithms. Looking ahead to 2026, HeartFlow targets a 25% revenue increase, aiming for a range between $218 million and $222 million. Gross margins are also projected to strengthen, reaching 80–81% in the near term with potential upside to 85% over the medium term. This positive outlook is supported by strong Q4 momentum and an expanding proprietary CT image database for coronary artery disease diagnostics. The company's scalable business model positions it as a key player in the high-growth AI healthcare sector.